Canada’s Nuvo completes acquisition of Aralez’ pharma unit for $110 mln

Canadian drugmaker Nuvo Pharmaceuticals Inc. has completed the previously announced acquisition of the specialty pharmaceutical business, formerly known as Tribute Pharmaceuticals Canada Inc., from peer Aralez Pharmaceuticals Inc.

Nuvo paid $110 million to Aralez at closing, which was funded via certain funds managed by healthcare investment firm Deerfield.

The acquired businesses include Cambia, BlextenTM, SuvexxTM, sold as Treximet in the U.S., as well as the Canadian distribution rights to Resultz, and will create a platform for Nuvo to acquire and launch additional commercial products in Canada.

Further, Nuvo has also purchased the worldwide rights and royalties for Vimovo, Yosprala and global product rights to MT400.